Sign inCreate account

Report workspace

Add to folder
NCT04219137RECRUITINGanonymous

Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study

Sponsor

Source record

University Health Network, Toronto

Phase

Source record

Observational

Modality

AI-normalized

gene therapy

Target

AI-normalized

Molecular characteristics and genomic profiling of gastroesophageal adenocarcinoma (GEA), including potential predictive signatures for treatment response.

Indication / condition

AI-normalized

Esophagogastric Adenocarcinoma

Intervention

Source record

Molecular Profiling

Related intelligence directories

Indication directory: Esophagogastric AdenocarcinomaModality directory: gene therapyTarget directory: Molecular characteristics and genomic profiling of gastroesophageal adenocarcinoma (GEA)

Source & freshness

Source record

NCT ID

NCT04219137

Original source

ClinicalTrials.gov

Source last updated

May 14, 2025

Ingested at

Jun 19, 2026

Internal sync

Jun 19, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04219137

Title

Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study

Sponsor

University Health Network, Toronto

Status

RECRUITING

Phase

Observational

Condition raw

Esophagogastric Adenocarcinoma

Condition normalized

Esophagogastric Adenocarcinoma

Modality raw

gene therapy

Modality normalized

gene therapy

Target raw

Molecular characteristics and genomic profiling of gastroesophageal adenocarcinoma (GEA), including potential predictive signatures for treatment response.

Target normalized

Molecular characteristics and genomic profiling of gastroesophageal adenocarcinoma (GEA), including potential predictive signatures for treatment response.

Interventions

Molecular Profiling

Public preview

Source record

The MOCHA study, sponsored by the University Health Network in Toronto, aims to enhance understanding of gastroesophageal adenocarcinoma through molecular profiling. This research could lead to personalized treatment protocols, potentially positioning the sponsor as a leader in GEA management. The market for GEA therapies is significant, with increasing demand for targeted treatments. The study's outcomes may inform future clinical trials and therapeutic strategies, impacting competitive positioning in the oncology landscape. Companies focusing on molecular diagnostics and personalized medicine may find collaboration or acquisition opportunities arising from the findings.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Molecular Characteristics of Gastroesophageal Adenocarcinoma (MOCHA): A Prospective Feasibility Study

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 19, 2026

NCT ID

NCT04219137

Status

RECRUITING

Phase

Observational

Sponsor

University Health Network, Toronto

Executive brief

Investment-Ready Snapshot

The MOCHA study, sponsored by the University Health Network in Toronto, aims to enhance understanding of gastroesophageal adenocarcinoma through molecular profiling. This research could lead to personalized treatment protocols, potentially positioning the sponsor as a leader in GEA management. The market for GEA therapies is significant, with increasing demand for targeted treatments. The study's outcomes may inform future clinical trials and therapeutic strategies, impacting competitive positioning in the oncology landscape. Companies focusing on molecular diagnostics and personalized medicine may find collaboration or acquisition opportunities arising from the findings.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 14, 2025
Internal syncJun 19, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04219137

Indication

Esophagogastric Adenocarcinoma

Modality

gene therapy

Target

Molecular characteristics and genomic profiling of gastroesophageal adenocarcinoma (GEA), including potential predictive signatures for treatment response.

Intervention

Molecular Profiling

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.